Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations
| Autor: | Qunhui WANG, Hua ZHENG, Fanbin HU, Hongmei ZHANG, Ying HU, Jie LI, Tongmei ZHANG, Zan LIU, Baohua LU, Aimin HU, Baolan LI |
|---|---|
| Jazyk: | čínština |
| Rok vydání: | 2016 |
| Předmět: | |
| Zdroj: | Chinese Journal of Lung Cancer, Vol 19, Iss 8, Pp 550-558 (2016) |
| Druh dokumentu: | article |
| ISSN: | 1009-3419 1999-6187 |
| DOI: | 10.3779/j.issn.1009-3419.2016.08.12 |
| Popis: | Background and objective Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the standard first-line treatment regimen for EGFR mutated non-small cell lung cancer (NSCLC) patients. However, the efficacy of EGFR-TKIs widely varies. The aim of this study is to determine whether the pretreatment serum cytokeratin-19 fragments (CYFRA21-1) and carcinoembryonic antigen (CEA) are associated with the efficacy of EGFR-TKIs in EGFR-mutated NSCLC patients. Methods We retrospectively enrolled 194 NSCLC patients harboring EGFR mutations who received EGFR-TKIs. Clinical characteristics were collected, and the relation between the efficacy of EGFR-TKIs and pretreatment serum CYFRA21-1 and CEA was analyzed. Results In all cases, progression-free survival (PFS) in patients with high CYFRA21-1 level was significantly shorter than PFS in patients with normal CYFRA21-1 (7.0 vs 11.9 months, P |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|